Vaginal Gel Blocks HIV, HerpesIngelore
Feb. 25, 2005 — A vaginal gel has strong HIV- and herpes-blocking action indeed an hour after use.
The gel is Pro 2000, presently in large-scale clinical tests. It’s trusted that the odorless, colorless item — what scientists call a vaginal microbicide — will moderate the spread of HIV and other sexually transmitted illnesses.
The modern discoveries come in a report by Mount Sinai School of Medicine analyst Marla Keller, MD, at this week’s 12th Conference on Retroviruses and Artful Diseases in Boston.
“There is an pressing need for the advancement of secure and successful vaginal microbicides,” Keller says, in a news release. “While condoms offer protection against sexually transmitted contaminations, their effectiveness is restricted since they require accomplice initiation or consent.”
A vaginal microbicide in this way offers women a way to protect themselves against HIV and STDs, even in the event that their sex partner refuses to utilize a condom.
Keller’s group arbitrarily gave Master 2000 — or an identical gel with no active ingredient — to 20 women with HIV contamination. An hour later, they collected vaginal fluids from each of the ladies. In lab ponders, they tested whether these vaginal liquids might avoid HIV or herpes infection of human cells.
Master 2000 treatment made it nearly 1,300 times harder for HIV to contaminate cells — nearly 500 times superior than placebo. Pro 2000 also made it 2,600 times harder for herpes simplex virus to contaminate cells — about 260 times better than fake treatment.
And there’s more great news: A microbicide won’t do much good if it causes incendiary responses that make vaginal tissues redden and swell. Investigation of Master 2000-treated fluids showed no sign of the chemical delivery people that trigger these undesirable responses.
The U.S. National Institute of Hypersensitivity and Infectious Diseases as of late announced the begin of a huge trial testing Pro 2000 and another vaginal microbicide, BufferGel. Not at all like Master 2000, which contains a virus-blocking specialist, BufferGel boosts the vagina’s common causticity, which ruins the capacity of the virus to infect cells. The 2.5-year trial will take put in Philadelphia, South Africa, Malawi, Tanzania, Zimbabwe, and Zambia.
Master 2000 is made by Indevus Pharmaceuticals, in Lexington, Mass. BufferGel is made by ReProtect Inc., in Baltimore, Md.